Ventilatory Parameters in Predicting Outcomes in ARDS Patients
NCT ID: NCT06400095
Last Updated: 2024-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2023-06-01
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Strategy of UltraProtective Lung Ventilation With Extracorporeal CO2 Removal for New-Onset Moderate to seVere ARDS
NCT02282657
Driving Pressure-guided Tidal Volume Ventilation in the Acute Respiratory Distress Syndrome
NCT06322758
Severe ARDS: Generating Evidence
NCT03021824
Flow-controlled Ventilation (FCV) in Moderate Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19
NCT04894214
Two Modes of Mechanical Ventilation for Intensive Care Patients With Low Blood Oxygen Due to Breathing Difficulties
NCT06140056
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Underassistance results in persistent atelectasis and resultant diffusion abnormalities and over-assistance causes ventilator-associated lung injury.
Mechanical power and driving pressure have been demonstrated to predict mortality in patients with Acute respiratory distress syndrome who are on mechanical ventilators. Mechanical work is the energy delivered to the respiratory system during a single inspiratory cycle and is calculated by solving the integral of airway pressure to change in volume. Mechanical power is work multiplied by RR(Respiratory rate). In the clinical setting, various equations have been used to calculate mechanical power. Mechanical Stress is defined as the internal distribution of force per unit area to an external load and associated deformation has been referred to as Strain. Stress is derived from specific lung elastance. Mechanical stress power is the power associated with internal forces required to maintain internal stresses within an object and is a part of mechanical power that is not converted to kinetic energy but rather into heat and change in internal energy.
The time constant is a measure of respiratory mechanics and is calculated by the product of compliance and resistance. Theoretically, it is the time needed for the lungs to fill or be emptied at a stable pressure. The expiratory time constant can indirectly represent lung heterogeneity during passive exhalation. It has been proposed that a shorter expiratory time constant can lead to VILI and a longer time constant can lead to hyperinflation and auto-PEEP.
The C20/C (Compliance 20/overall compliance) index measures the ratio of compliance of the last 20% of breath to the compliance of the entire breath. It is believed that C20/C \> 1 indicates tidal recruitment and C20/C \< 1 indicates overinflation.
Pulmonary dead space fraction ( Vd/Vt) is an independent predictor of mortality after adjusting for PF ratio and PEEP. The ventilatory ratio has been proposed as a simplified bedside tool as a surrogate for the dead space ratio. Ventilatory Ratio (VR) is defined as minute ventilation ( ml/min) \* PaCO2/Predicted body weight \* 100\* 37.5.
For those patients, who satisfy inclusion and exclusion criteria, Day 1 will be considered as the the day of intubation. Age, gender, Charleston co-morbidity index, SOFA (Sequential organ function assessment) score at the time of intubation. For day 1 to day 3, we shall record average values of Pocc, TCe, C20/C index, Ventilatory ratio, Mechanical stress power, and PF ratio (PaO2/FiO2 ratio) will be recorded. Outcome data such as the need for vasopressors, prone position, duration of ICU stay, MAKE outcomes, need for paralysis, change in the mode of ventilator, ventilator number of days, hospital stay and 30-day outcomes including disability and survival.
Statistical Analysis:
Only de-identified data will be recorded on the spreadsheet.
Baseline demographic features and descriptive clinical data will be summarized using means +/- SDs or medians with interquartile ranges (IQR) for continuous variables. Percentages will be used for categorical variables. For normally distributed data, t test will be used to compare the two groups. For skewed data or categorical data, a non-parametric Mann-Whitney U test and Kruskal-Wallis test will be used. For categorical data, comparisons will be made using a Pearson or chi-square or the Fisher exact test as appropriate. for more than two groups, one-way ANOVA (Analysis of variance) will be employed. The receiver operating characteristic approach will be used to identify the clinical significance of each of these variables. Univariate analysis will be performed to identify predictors of outcomes. If any factors are found significant, data will be subjected to multivariate logistic regression analysis and the corresponding adjusted odds ratio will be calculated. Pearson correlation and Bland-Altman analysis will be used as needed. For all comparisons, a p-value of \< 0.05 is considered significant. Jamovi will be used for statistical analysis.
Only de-identified data will be recorded on the spreadsheet
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Poccl, Time constant, driving pressure
Ventilatory parameters
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of Severe ARDS with severity: PF ratio \< 150, with PEEP/CPAP \> 5
Exclusion Criteria
* Expiratory flow that is not first-order or non-exponential decay
* Patients with Nor-epinephrine requirements \> 0.1 mcg/kg/min within 2 hours of intubation
* Patients requiring ECMO ( Extracorporeal membrane oxygenation)
* Patients with COPD or pulmonary fibrosis with a premorbid FEV1 \< 1.5 L
* Severe atherosclerotic vascular disease
* Patients with a chest tube, intra-abdominal hypertension or with its risk factors
* Patients with structural heart disease including pulmonary hypertension (RVSP \> 45) and heart failure
* All comfort care orders in the ICU
* Patients who underwent tracheostomy
19 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CentraCare
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ramakanth Pata
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ramakanth Pata, MD FCCP
Role: PRINCIPAL_INVESTIGATOR
Centracare health System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St Cloud Hospital
Saint Cloud, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Paudel R, Trinkle CA, Waters CM, Robinson LE, Cassity E, Sturgill JL, Broaddus R, Morris PE. Mechanical Power: A New Concept in Mechanical Ventilation. Am J Med Sci. 2021 Dec;362(6):537-545. doi: 10.1016/j.amjms.2021.09.004. Epub 2021 Sep 28.
Guttmann J, Eberhard L, Fabry B, Bertschmann W, Zeravik J, Adolph M, Eckart J, Wolff G. Time constant/volume relationship of passive expiration in mechanically ventilated ARDS patients. Eur Respir J. 1995 Jan;8(1):114-20. doi: 10.1183/09031936.95.08010114.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RAMOCTANE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.